Journal of Diabetes Research, 2022 Background. GLP-1 receptor agonists (GLP-1RA) are common clinical agents that are clinically protective against diabetic complications, such as diabetic retinopathy (DR).
Liufeng Wei +11 more
doaj +1 more source
Frontiers in Endocrinology, 2022 BackgroundsRobust evidence have demonstrated the beneficial effect of Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in T2D patients with cardiovascular diseases and chronic kidney disease ...
Cao Li +7 more
doaj +1 more source
A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks. DUAL VIII, a randomized trial designed to resemble clinical practice [PDF]
, 2020 This report presents the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as initial injectable therapy at 26 weeks in the 104-week DUAL VIII durability trial (NCT02501161). Participants (N =
Aroda, V. R. +7 more
core +1 more source
EClinicalMedicine, 2023 Summary: Background: Innovative GLP-1 receptor agonist (GLP-1RA)-based treatment strategies—such as tirzepatide, GLP-1RA plus basal insulin fixed-ratio combinations [FRC], GLP-1RA plus sodium glucose cotransporter-2 inhibitors [SGLT-2i] combinations ...
Irene Caruso +10 more
doaj +1 more source
Semaglutide seems to be more effective the other GLP-1Ras [PDF]
Annals of Translational Medicine, 2017 Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were introduced as treatment options for type 2 diabetes (T2DM) in 2005 (1). They have become popular because of their efficacy and durability in relation to glycaemic control, and their low risk of hypoglycaemia in combination with weight loss in most patients (2,3).
Holst, Jens Juul, Madsbad, Sten
openaire +3 more sources
The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors:A Danish nationwide cohort study [PDF]
, 2022 BACKGROUND: Type 2 diabetes mellitus (T2D) is associated with an increased fracture risk. There is little evidence for the effects of glucagon-like peptide 1 receptor agonists (GLP-1RA) on fracture risk in T2D.
Al-Mashhadi, Zheer Kejlberg +5 more
core +3 more sources
Data mining approach to estimate the duration of drug therapy from longitudinal electronic medical records [PDF]
, 2017 Background: Electronic Medical Records (EMRs) from primary/ ambulatory care systems present a new and promising source of information for conducting clinical and translational research.
Arandelovic, Ognjen +3 more
core +1 more source
Cardiovascular Diabetology, 2023 Background There are limited data on head-to-head comparative risk of stroke between sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA).
David Tak Wai Lui +7 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020 Background We investigated the effects of insulin, glucagon‐like peptide‐1 receptor agonists (GLP‐1RA), sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i), and their combination on vascular and cardiac function of patients with type 2 diabetes mellitus.
Ignatios Ikonomidis +14 more
doaj +1 more source
Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies [PDF]
, 2021 Introduction: The aim of this study was to elaborate a consensus on treatment intensification strategies in patients with type 2 diabetes failing basal insulin supported oral therapy (BOT).
Candido, Riccardo +5 more
core +1 more source